Further investigations need to be carried out in order to confirm the safety and evaluate the possible efficacy of the G-CSF in Chagas cardiomyopathy, possibly testing the administration of G-CSF earlier in the course of the disease, and with a longer follow-up period. This evidence concerns the gene CSF3 and Chagas cardiomyopathy.